What if the trick to getting cancer immunotherapy to parts of the world that can’t access it is simply lowering the dose? A ...
Read more about ASCO results showing improved survival with TMC-I in recurrent or metastatic head and neck cancer.
J&J’s amivantamab (Rybrevant Faspro) shows a 42% response rate in advanced head & neck cancer, boosting FDA approval odds—see ...
MedPage Today on MSN
Ultra-low-dose immunotherapy may benefit cancer patients in low-resource countries
Regimen showed benefit in advanced head and neck cancer ...
Clinical Trials Arena on MSN
ASCO26: Cancer vaccines and at-home injectable drugs continue to show promise
A number of companies presented new data on their cancer vaccine candidates at ASCO 2026.
IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an ...
Prognosis is extremely poor for patients with head and neck squamous cell carcinoma (HNSCC), which accounts for around 90% of all head and neck cancer. Especially in the more aggressive subtype of ...
Despite recent advances in immunotherapy and targeted therapy, most patients with non-small-cell lung cancer (NSCLC) continue to have disease progression and develop resistance to current treatments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results